What drove NPCE's earnings surge in Q3 2024?

NeuroPace's earnings surge in Q3 2024 can be attributed to **Increased Sales of RNS System** and **Growth in Dixie Medical Products**:

1. **RNS System Sales Growth**: The company reported a 27% year-over-year increase in RNS system sales, which is a significant contributor to the revenue growth. This increase reflects the growing demand for NeuroPace's innovative RNS System, which is designed to treat drug-resistant epilepsy.
2. **Dixie Medical Products**: In addition to the RNS System, NeuroPace's growth has also been driven by higher sales of Dixie Medical stereo EEG products. The company's exclusive partnership with Dixie Medical has led to increased revenue from these products, which has contributed to the overall financial performance.

Overall, the combination of increased sales of their core product, the RNS System, and the growth from Dixie Medical Products have driven NeuroPace's earnings surge in Q3 2024.